Airtek aerosol for inhalation metered 25/250 mcg/dose, 120 doses — Made in India — Free Delivery

Product description

Aerosol Airtek is intended for the treatment of bronchial asthma in patients who are indicated for combination therapy with long-acting ß2-adrenergic agonists and inhaled corticosteroids, namely:

• in case of insufficient control of the disease against the background of constant monotherapy with inhaled corticosteroids with periodic use of short-acting β2-adrenomimetics;
• in the case of adequate control of the disease during therapy with inhaled corticosteroids and long-acting β2-adrenergic agonists.

Structure

Active ingredients: salmeterol (in the form of salmeterol xinafoate) and fluticasone propionate;

1 dose contains salmeterol xinafoate equivalent to salmeterol - 25 mcg and fluticasone propionate - 250 mcg.

Excipients: propellant 1,1,1,2-tetrafluoroethane (HFA 134a), polyethylene glycol 1000.

Contraindications

Hypersensitivity to the components of the drug.

Mode of application

Adults and children over 12 years old: 2 inhalations of 25 mcg salmeterol / 50 mcg fluticasone propionate 2 times a day or 2 inhalations of 25 mcg salmeterol / 125 mcg fluticasone propionate 2 times a day, or 2 inhalations of 25 mcg salmeterol / 250 mcg fluticasone propionate 2 times per day.

Children 4-12 years old: 2 inhalations of 25 mcg of salmeterol and 50 mcg of fluticasone propionate 2 times a day. The maximum daily dose of fluticasone propionate is 100 mcg 2 times a day.

Application features

Pregnant

The appointment of Airtek during pregnancy is advisable only in cases where the expected benefit to the mother outweighs the possible risk to the fetus. For the treatment of pregnant women, low effective doses of fluticasone propionate are prescribed to maintain adequate control of asthma symptoms.

Children

Children and adolescents under the age of 16 who are treated with high doses of fluticasone propionate (usually ≥1000 mcg / day) are at particular risk of systemic effects. Systemic effects are usually caused by treatment at high doses for a long time. Possible systemic effects include Cushing's syndrome, cushingoid symptoms, suppression of adrenal function, acute adrenal crisis, stunted growth in children and adolescents, decreased bone mineralization, cataracts and glaucoma, less often possible mental disorders and behavior changes, including psychomotor hyperactivity, sleep disturbances, agitation, depression or aggression.

It is recommended to regularly monitor the growth dynamics of children receiving inhaled corticosteroids for a long time. The dose of inhaled corticosteroids should be reduced to the minimum effective dose to control asthma symptoms.

Overdose

Signs and symptoms that can be expected with salmeterol overdose, typical of β2-agonist overstimulation, include dizziness, tremors, headache, tachycardia, and increased systolic blood pressure. If treatment with the drug must be discontinued as a result of an overdose of the β2-agonist included in the drug, appropriate steroid replacement therapy should be prescribed. Additionally, hypokalemia may occur, therefore, serum potassium levels should be monitored and the need for potassium replacement therapy should be taken into account.

Side effects

• nasopharyngitis;
• throat irritation;
• Hoarseness / dysphonia;
• sinusitis;
• paradoxical bronchospasm;
• muscle spasms;
• arthralgia;
• myalgia.

Interaction

Due to the risk of developing bronchospasm, the use of selective and non-selective β-blockers should be avoided, except in those cases when they are very necessary for the patient.

Concomitant use with drugs containing other β-adrenergic drugs may have a potential additive effect.

Storage conditions

Store at a temperature not exceeding 30⁰С. Do not freeze.

Keep out of the reach of children.

Shelf life is 2 years.